• Publications
  • Influence
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen:
Adjuvant RT for pT3 prostate cancer with postoperatively undetectable PSA significantly reduces the risk of biochemical progression and further follow-up is needed to assess the effect on metastases-free and overall survival.
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Among patients with macroscopically completely removed pancreatic cancer, the use of adjuvant gemcitabine for 6 months compared with observation alone resulted in increased overall survival as well as disease-free survival, providing strong support for the use in this setting.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
Based on a preliminary subgroup analysis, pancreatic cancer patients with a good PS appear to benefit from GEM-based cytotoxic combinations, whereas patients with an initially poor PS seem to have no survival benefit from combination chemotherapy.
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
The results suggest that rituximab has clinical activity in pretreated patients with B-CLL and toxicity is tolerable, and other modes of application and the combination with other agents need to be tested.
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
CAPOX resulted in a slightly inferior efficacy than FUFOX, and the best estimate of the HR of 1.17 was within the prespecified equivalence range, however, a relevant inferiority cannot be excluded.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Thalidomide-dexamethasone with melphalan-prednisolone resulted in a higher proportion of complete and very good remissions, and overall responses, compared with MP, and Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status.